With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

AnaptysBio $ANAB CEO Hamza Suria is counting up the money he’s due from GlaxoSmithKline.

GSK’s Hal Barron inherited a partnership with AnaptysBio when he …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With FDA de­ci­sion loom­ing, GSK sweet­ens the PD-1 pot for dis­cov­ery part­ner Anap­tys­Bio as Hal Bar­ron moves to guard his on­col­o­gy strat­e­gy